Advertisement

Journal of Immigrant and Minority Health

, Volume 9, Issue 1, pp 43–47 | Cite as

The Sero-Prevalence of Antibodies to Trypanosoma cruzi in Latin American Refugees and Immigrants to Canada

  • L. S. SteeleEmail author
  • D. W. MacPherson
  • J. Kim
  • J. S. Keystone
  • B. D. Gushulak
Original Paper

Abstract

Background: Chagas’ disease is caused by infection with the protozoan agent Trypanosoma cruzi. An estimated sixteen to eighteen million people are infected in Latin America. Outside of endemic regions, Chagas’ disease may be transmitted through the transfusion of infected blood components, congenital infection and organ transplantation. We sought to determine the sero-prevalence of antibodies to T. cruzi in a community sample of Latin American refugees and immigrants to Canada.

Methods: This was a sero-prevalence study in Latin American refugees and immigrants living in Canada. Eligible subjects were born in South America, Central America or in Mexico. Participants were recruited from a variety of community settings, as well as from medical clinics. Serum was tested by enzyme-linked immunoassay for antibodies to T. cruzi.

Results: A total of 102 participants were enrolled. One sample tested positive for antibodies for T. cruzi. The seroprevalence in our sample was 1.0% (95% CI: 0.2%- 5.3%).

Interpretation: We found a low sero-prevalence of Chagas’ disease in a community sample of Latin American immigrants and refugees. Physicians who treat Latin American immigrants should consider the risk profile and clinical status of the individual in their decision to screen for Chagas’ disease.

Keywords

Chagas’ disease Trypanosoma cruzi Sero-prevalence Immigrants and refugees Latin America Canada 

Notes

Acknowledgements

Special thanks to Wendy MacQueen, Regional Parasitology Laboratory, Hamilton Regional Laboratory Medicine Program (St. Joseph’s site), Hamilton, Ontario who did all of the serological testing for this study. The study received funding from Health Canada. Dr. Steele is supported by a career scientist award from the Ontario Ministry of Health and Long Term Care and she is supported as a research scholar by the Department of Family and Community Medicine at the University of Toronto.

References

  1. 1.
    Moncayo A: Chagas disease: Current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003; 98:577–91PubMedCrossRefGoogle Scholar
  2. 2.
    Prata A: Clinical and epidemiological aspects of Chagas’ disease. Lancet Inf Diseases 2000; 1:92–100CrossRefGoogle Scholar
  3. 3.
    Schmunis GA: Trypanosoma cruzi, the etiologic agent of Chagas’ disease: status in the blood supply in endemic and non-endemic countries. Transfusion 1991; 31:547–555PubMedCrossRefGoogle Scholar
  4. 4.
    Kerndt PR, Waskin HA, Kischhoff LV, Steurer F, Waterman SH, Nelson JM, et al.: Prevalence of antibody to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion 1991; 31:814–818PubMedCrossRefGoogle Scholar
  5. 5.
    Leiby DA, Read EJ, Lenes BA, Yund AJ, Stumpt RJ, Kirchhoff LV, et al.: Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas’ disease, in US blood donors. J Infect Dis 1997; 176:1047–1052PubMedCrossRefGoogle Scholar
  6. 6.
    Shulman IA, Appleman MD, Saxena S, Hiti AL, Kirchhoff LV: Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion 1997; 37:727–818PubMedCrossRefGoogle Scholar
  7. 7.
    Barrett VJ, Leiby DA, Odom JL, Otani MM, Rowe JD, Root JT, et al.: Negligible prevalence of antibodies against Trypanosoma cruzi among blood donors in the Southeastern United States. Am J Clin Path 1997; 108:499–503PubMedGoogle Scholar
  8. 8.
    Skolnick A: Deferral aims to deter Chagas’ parasite. JAMA 1991;265:173PubMedCrossRefGoogle Scholar
  9. 9.
    Nickerson P, Orr P, Schroeder ML, Sekla L, Johnston JB: Transfusion-associated Trypanosoma cruzi infection in a non-endemic area. Ann Intern Med 1989; 111:851–853PubMedGoogle Scholar
  10. 10.
    World Health Organization: Control of Chagas’ Disease. WHO Technical Report Series, World Health Organization 1991; 811:1–94Google Scholar
  11. 11.
    Kirchhoff LV, Gamm AA, Gilliam FC: American trypanosomiasis (Chagas’ disease) in Central American immigrants. Am J Med 1987; 82:915–920PubMedCrossRefGoogle Scholar
  12. 12.
    Frank M, Hegenscheid B, Janitschke K, Weinke T: Prevalence and epidemiological significance of Trypanosoma cruzi infection among Latin American immigrants in Berlin, Germany. Infection 1997; 25:355–358PubMedCrossRefGoogle Scholar
  13. 13.
    Braschear RJ, Winkler MA, Schur JD, Lee H, Burczak JD, Hall HJ, et al.: Detection of antibodies to Trypanosoma cruzi among blood donors in the southwestern and western United States. I. Evaluation of the sensitivity and specificity of an enzyme immunoassay for detecting antibodies to T. cruzi. Transfusion 1995; 35:213–218CrossRefGoogle Scholar
  14. 14.
    Chagas’ Disease: Frequency and geographical distribution. Weekly Epidemiol Rec 1990; 65:257–264Google Scholar
  15. 15.
    Statistics Canada: Immigrant population by place of birth for Canada. 2001 CensusGoogle Scholar
  16. 16.
    Rassi A Jr., Rassi A, Little WC: Chagas’ heart disease. Clin Cardiol 2000; 23:883–889PubMedCrossRefGoogle Scholar
  17. 17.
    Freilij H, Altchech J: Congenital Chagas’ disease: Diagnostic and clinical aspects. Clin Infect Dis 1995; 21:551–555PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • L. S. Steele
    • 1
    • 6
    Email author
  • D. W. MacPherson
    • 2
    • 5
  • J. Kim
    • 3
  • J. S. Keystone
    • 4
  • B. D. Gushulak
    • 5
  1. 1.Department of Family and Community MedicineSt. Michael’s HospitalTorontoCanada
  2. 2.Faculty of Health SciencesMcMaster UniversityHamiltonCanada
  3. 3.Department of Family and Community MedicineUniversity of TorontoTorontoCanada
  4. 4.Department of Medicine and PathologyUniversity of TorontoTorontoCanada
  5. 5.Migration Health Consultants Inc.CheltenhamCanada
  6. 6.Health Systems Research and Consulting UnitCentre for Addiction and Mental HealthTorontoCannda

Personalised recommendations